Is Exelixis, Inc. (EXEL) a Buy, Sell, or Hold?
Exelixis, Inc.
NASDAQ:EXEL
$55.77 USD
-$0.27 (-0.48%)
- Volume
- 1.8M
- Average Volume
- 2.74M
- Market Capitalization
- $14.02B
- P/E Ratio
- 17.87
- Dividend Yield
- 0.00%
- Price Target
- $49.00
- Year High
- $57.57
- Year Low
- $33.76
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.26
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael Morrissey |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | EXEL |
| CUSIP | 30161Q104 |
| CIK | 0000939767 |
| Web | https://www.exelixis.com |
| Phone | 650 837 7000 |
| Currency | USD |
| Employees | 1077 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.09 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.26 |
| Quick Ratio | 3.19 |
| Cash Ratio | 0.61 |
Sales & Book Value
| Annual Sales | $2.32B |
| Price / Sales | 5.90 |
| Cash Flow | 3.55 |
| Price / Cash Flow | 15.30 |
| Price / Book | 7.44 |
Price Target and Rating
| Average Stock Price Forecast | $49.00 |
| High Stock Price Forecast | $56.00 |
| Low Stock Price Forecast | $44.00 |
| Forecast Upside/Downside | 13.82% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 33 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.78 |
| Trailing P/E Ratio | 17.87 |
| PEG Ratio | 0.46 |
| P/E Growth | 0.46 |
| Net Income | $782.57M |
| Net Margin | 35.08% |
| Pretax Margin | 42.23% |
| Return on Equity | 40.21% |
| Return on Assets | 32.13% |
Financials Score
| AltmanZ Score | 15.29 |
| Piotroski Score | 7.00 |
| Working Capital | 837.66M |
| Total Assets | 2.59B |
| Ebit | 986.42M |
| Market Cap | 14.09B |
| Total Liabilities | 657.84M |
Poll Results
About Exelixis, Inc. (NASDAQ:EXEL) Stock
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administ ... ered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
3 Under-the-Radar Stocks to Buy and Hold
2026-07-10 14:30:00
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
2026-07-09 15:26:07
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Stocks Look Shaky, But This Sector is Booming (Biotech)
2026-07-09 14:06:06
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
2026-07-09 10:46:10
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
2026-07-08 12:41:11
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
2026-07-08 10:16:08
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
2026-07-06 10:40:37
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
2026-06-23 15:26:06
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
Frequently Asked Questions
-
What is the current Exelixis, Inc. (EXEL) stock price?
-
Exelixis, Inc.(NASDAQ:EXEL) stock price is $55.77 in the last trading session. During the trading session, EXEL stock reached the peak price of $57.57 while $33.76 was the lowest point it dropped to. The percentage change in EXEL stock occurred in the recent session was --0.48% while the dollar amount for the price change in EXEL stock was -$-0.27.
-
EXEL's industry and sector of operation?
-
The NASDAQ listed EXEL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EXEL?
-
Stelios Papadopoulos | Co-Founder & Independent Chair of the Board
Dana T. Aftab | Executive Vice President of Research & Development
Stefan Krauss | Vice President & Head of Business Development
William Berg | Senior Vice President of Medical Affairs
Andrew Ross Peters | Senior Vice President of Strategy -
How many employees does EXEL have?
-
Number of EXEL employees currently stands at 1077. EXEL operates from 1851 Harbor Bay Parkway, Alameda, CA 94502, US.
-
Link for EXEL official website?
-
Official Website of EXEL is: https://www.exelixis.com
-
How do I contact EXEL?
-
EXEL could be contacted at phone #650 837 7000 and can also be accessed through its website. EXEL operates from 1851 Harbor Bay Parkway, Alameda, CA 94502, US.
-
How many shares of EXEL are traded daily?
-
The average number of EXEL shares traded daily for last 3 months was 2.74M.
-
What is the market cap of EXEL currently?
-
The market value of EXEL currently stands at $14.02B with its latest stock price at $55.77